HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.

HBV-IN-38 (Example 193), an HBV DNA inhibitor with an EC50 value of ≤100 nM, serves as a research tool for investigating viral infections [1].

HBV-IN-6 is a potent inhibitor of HBV (EC50: 5 nM).

HBV Seq1 aa:93-100 is a hepatitis B virus (HBV) core antigen 93-100 peptide fragment [1] .

HBV-IN-17 (compound 8) is a potent regulator of HBV capsid assembly (EC50: 511 nM).

HBV-IN-9 (example 20) is a potent inhibitor of HBsAg (HBV surface antigen) with an IC50 value of 10 nM. HBV-IN-9 (example 20) is also an inhibitor of HBV DNA replication with an IC50 value of 0.15 nM.

HBV-IN-41 (compound 45) is a potent, orally active inhibitor of Hepatitis B Virus (HBV), exhibiting an EC50 value of 0.027μM [1].

HBV-IN-18 (Compound 3) is an HBV capsid assembly modulator (CpAM) (EC50: 2790 nM).

HBV-IN-15, a flavone derivative, acts as a potent inhibitor of covalently closed circular DNA (cccDNA), which is crucial for viral RNA transcription and subsequent viral DNA production. This compound shows promise for research in Hepatitis B Virus (HBV) infection.

HBV-IN-30 (ex44), a flavone derivative, acts as a potent inhibitor of covalently closed circular DNA (cccDNA), which is essential for viral RNA transcription and subsequent viral DNA production. This compound shows promise for researching hepatitis B virus (HBV) infection.

HBV Seq2 aa:179-186, a novel epitope located on the hepatitis B virus surface antigen, effectively serves as a motif for CTL response within the H-2b system following in vitro restimulation of primed T cells [1].

HBV Seq2 aa:208-216, a CD8 epitope peptide derived from HBsAg, is investigated within the context of the Large envelope protein from the Hepatitis B virus [1].

HBV Seq1 aa:18-27 is a hepatitis B virus (HBV) core antigen 18-27 peptide fragment [1] .

(5S,8R)-HBV-IN-10 is an isomer of compound 6 (WO2021204258A1). Compound 6 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.1 μM< EC50≤1 μM).

HBV-IN19 TFA inhibits the secretion and/or production of HBsAg and has an inhibitory effect on hepatitis B virus (HBV) infection and can be used in studies of HBV infection, including chronic HBV infection.

HBV-IN-6 is a potent inhibitor of HBV (EC50: 287.9 nM).

HBV-IN-31, a potent inhibitor of covalently closed circular DNA (cccDNA), demonstrates significant anti-HBV activity by inhibiting cell growth and exhibiting an IC50 value of 0.13 µM for HBsAg.

HBV Seq1 aa:141-151 is a peptide useful in the research of chronic hepatitis B virus (HBV) [1].

HBV-IN-11 is a potent inhibitor of HBsAg secretion (EC50: 0.46 μM).

HBV-IN-14 is a pyridinopyrimidinone compound and a potent covalent closed-loop DNA (cccDNA) inhibitor. HBV-IN-14 has potential for the study of HBV infection.

HBV-IN-16 is a quinoline derivative, which has an effective inhibitory effect on covalent closed circular DNA (cccDNA). CccDNA is the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 has potential in the research of HBV infection.

HBV-IN-6 is a potent inhibitor of HBV (EC50: 44 nM).

HBV-IN-36 (also known as compound 42) is a hepatitis B virus (HBV) inhibitor with an IC50 of 2 μM, exhibiting anti-HBV activity characterized by an EC50 of 0.58 μM [1].

Compound HBV-IN-35 (Compound 88) serves as an HBV inhibitor and exhibits anti-HBV activity in both mouse and human hepatocytes with EC50 values of 100 nM and 400 nM, respectively [1].

HBV-IN-34 (compound 17i) is a potent inhibitor of HBsAg production, demonstrating remarkable in vitro anti-HBV efficacy with EC50 values of 0.018 μM for HBV DNA and 0.044 μM for HBsAg [1].

HBV-IN-25 is a novel chemical compound that acts as a potent HBV cccDNA reducer when administered orally. It exhibits significant anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. Moreover, HBV-IN-25 demonstrates favorable aqueous solubility (LYSA＞452 μg/mL) and no cellular toxicity, making it a promising candidate for further investigation and development [1].

HBV-IN-32, a potent inhibitor of covalently closed circular DNA (cccDNA), exhibits significant anti-Hepatitis B Virus (HBV) activity by achieving an IC50 of 0.14 µM against HBsAg. Additionally, it impedes cell growth.

HBV-IN-4, a derivative of phthalazinone, functions as a potent, orally active inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. It effectively induces the formation of genome-free capsids, demonstrating significant anti-HBV potency[1].

HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg).

HBV-IN-20 is a potent, orally active HBV inhibitor (EC50: 0.46 μM). HBV-IN-20 is a classical type II CpAM (core protein assembly regulator).

HBV Seq1 aa:63-71 is the fragment of hepatitis B virus (HBV) [1] .

HBV-IN-10 is an isomer of compound 6 (WO2021204258A1). Compound 6 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.1 μM < EC50 ≤ 1 μM).

HBV-IN-21 (Compound II-8b) is a potent inhibitor of HBV DNA replication, exhibiting an IC50 of 2.2 μM. It demonstrates a favorable binding affinity (K D = 60.0 μM) for the HBV 4 capsid protein, thereby enabling effective interaction [1].

HBV-IN-40 (Compound 11826096), with an IC50 of 0.7 µM, serves as a potent HBV inhibitor and exhibits antiviral activity [1].

HBV-IN19 has inhibitory effects on hepatitis B virus (HBV) infection. HBV-IN19 inhibits HBsAg secretion and/or production and can be used in the study of HBV infection (e.g. chronic HBV infection).

HBV-IN-24 (compound (2 S, 6S)-1a) is a potent inhibitor of HBV. HBV-IN-24 is a strong inhibitor of HBV DNA (EC50: 0.6 nM), HBsAg (EC50: 0.6 nM) and HBeAg (EC50: 4.6 nM). antiviral effect and was able to improve neurotoxicity.

HBV-IN-29 (ex8), a flavone derivative, functions as a potent inhibitor of covalently closed circular DNA (cccDNA), which is essential for viral RNA transcription and subsequent viral DNA replication. This compound shows promise in the study of HBV infection.

HBV-IN-22 (Compound LC5f) is an HBV DNA replication inhibitor that acts on both wild-type HBV (IC50: 0.71 μM) and drug-resistant HBV (IC50: 0.84 μM).

HBV Seq2 aa:28-39, a Hepatitis B surface antigen (HBsAg) peptide, specifically binds to Major Histocompatibility Complex (MHC) class I molecules, as evidenced in sources [1] [2].

HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.001 μM < EC50 ≤ 0.05 μM). HBV-IN-12 is anti-HBV DNA (0.001 μM < EC50 ≤ 0.02 μM).

HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication (IC50: 0.58 μM). HBV-IN-23 inhibits drug-sensitive and drug-resistant strains. HBV-IN-23 induces apoptosis in HepG2 cells and exhibits anti-hepatocellular carcinoma (HCC) effects.

Bulevirtide (Myrcludex B) acetate is a virion entry inhibitor which blocks the virion's hepatocyte pathway of entry, the hepatic sodium/taurocholate cotransporting polypeptide (NTCP) receptor. Bulevirtide (Myrcludex B) acetate can be used in HBV and HDV infection studies.

Doxorubicin hydrochloride (Adriamycin) belongs to the anthracycline class of antibiotics and is an inhibitor of human DNA topoisomerase I/II (IC50=0.8/2.67 μM). Doxorubicin hydrochloride exhibits cytotoxicity and antitumor activity. Doxorubicin hydrochloride reduces the phosphorylation of AMPK and its downstream target protein acetyl coenzyme A carboxylase, and induces apoptosis and autophagy.

Tenofovir (GS 1278) is an adenine analog REVERSE TRANSC-RIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.

Catalpol (Catalpinoside) is an iridoid glycoside with neuroprotective, anti-inflammatory, and anti-hepatitis virus effects.

Tenofovir Disoproxil Fumarate (GS-1278 Disoproxil Fumarate) is a pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.

Thiamine hydrochloride (Vitamin B1) is the hydrochloride salt form of thiamine, a vitamin essential for aerobic metabolism, cell growth, transmission of nerve impulses and acetylcholine synthesis. Upon hydrolysis, Thiamine hydrochloride (Vitamin B1) is phosphorylated by thiamine diphosphokinase to form active thiamine pyrophosphate (TPP), also known as cocarboxylase. TPP is a coenzyme for many enzymatic activities involving fatty acid, amino acid and carbohydrate metabolism.

Metformin-d6 hydrochloride (Metformin-d6 hydrochloride) is a deuterated form of Metformin that can be used to study Metformin metabolism in vivo, and is often used as an internal standard for Metformin.ccc_R08 can be used to study HBV infection.ccc_R08 can be used to study HBV infection.

Bifendate (Bifendatatum) is commonly used to treat the transaminase elevation that caused by viral hepatitis and drug-induced liver injury.

Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Metformin embonate is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Metformin glycinate is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Metformin icosapent is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Metformin (1,1-Dimethylbiguanide) is an AMPK activator with blood-brain barrier permeability. Metformin may improve glycemic control by increasing insulin sensitivity and decreasing intestinal glucose uptake, and is commonly used in type 2 diabetes research.

Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) , a widely used anti-diabetic drug, has a potential function as an anti-Y medicine. It inhibits the proliferation of a variety of Y cells including colon, prostate, and etc.